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HLA‑G is a promiscuous immune checkpoint molecule. The HLA‑G gene presents substantial 
nucleotide variability in its regulatory regions. However, it encodes a limited number of proteins 
compared to classical HLA class I genes. We characterized the HLA‑G genetic variability in 4640 
individuals from 88 different population samples across the globe by using a state‑of‑the‑art method 
to characterize polymorphisms and haplotypes from high‑coverage next‑generation sequencing 
data. We also provide insights regarding the HLA‑G genetic diversity and a resource for future 
studies evaluating HLA‑G polymorphisms in different populations and association studies. Despite 
the great haplotype variability, we demonstrated that: (1) most of the HLA‑G polymorphisms are 
in introns and regulatory sequences, and these are the sites with evidence of balancing selection, 
(2) linkage disequilibrium is high throughout the gene, extending up to HLA‑A, (3) there are few 
proteins frequently observed in worldwide populations, with lack of variation in residues associated 
with major HLA‑G biological properties (dimer formation, interaction with leukocyte receptors). 
These observations corroborate the role of HLA‑G as an immune checkpoint molecule rather than as 
an antigen‑presenting molecule. Understanding HLA‑G variability across populations is relevant for 
disease association and functional studies.
The human leukocyte antigen G (HLA-G) belongs to the family of non-classical HLA class I molecules, first iden-
tified at the maternal–fetal interface, especially on the placenta’s cytotrophoblast cells, where immunotolerance 
contributes to the fetus maintenance. The HLA-G molecule is considered a promiscuous immune checkpoint 
molecule, inhibiting antigen-presenting cells, T, B, and NK lymphocytes, through the interaction with several 
leukocyte receptors, including ILT2, ILT4, CD160, KIR2DL4, and CD8  receptors1. ILT2 and ILT4 also interact 
with some classical class I HLA molecules but have more affinity for HLA-G2, and KIR2DL4 is a specific receptor 
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for HLA-G3,4. HLA-G ligation with these receptors modulates T cytotoxic and NK cell activity, inducing the 
expression of inhibitory receptors containing Tyrosine  motifs5.
HLA-G deserves special attention in pregnancy because HLA-G plays a role in immunosuppression and 
homeostasis maintenance during  pregnancy6. Therefore, the non-expression of classical HLA class I molecules 
by the trophoblastic cells make them potential targets for the lysis mediated by NK cells and the interaction of the 
HLA-G molecule (trophoblast) with uterine NK inhibitor receptors hampers the trophoblast cell  lysis7. HLA-G 
also activates the production of cytokines that promote remodeling of the vascularization at the maternal–fetal 
region, of major importance for oxygen supply to the  fetus8–10. HLA-G deregulation is also important in patho-
logical situations such as tumors and autoimmune diseases. HLA-G polymorphisms and expression levels have 
been associated with susceptibility to infections, tumors, and autoimmune  diseases11–16.
At least seven HLA-G isoforms have been described by alternative splicing of the primary transcript, encoding 
four membrane-bound (G1-G4) and three soluble (G5-G7) isoforms, and their presence in tissue cells may be 
benefic or pernicious, depending on the underlying  condition15,17. However, rare isoforms have been detected 
in tumor  samples18.
The HLA-G coding region presents similarities to the classical HLA class I genes. While most HLA genes are 
extremely polymorphic, HLA-G is highly conserved in its coding nucleotide sequence, presenting a much lower 
number of different haplotypes, defined mainly by polymorphisms that span around putative regulatory regions 
and introns. In the IPD-IMGT/HLA  database19, release 3.45.1 from July 2021, HLA-G exhibited 88 alleles (dif-
ferent sequences), encoding 26 allotypes, but few are frequent, as demonstrated later in this study. The HLA-G 
coding region is relatively conserved, exhibiting few functional polymorphisms (e.g., non-synonymous variants); 
however, the HLA-G regulatory regions are more variable, displaying target sites for many transcriptional and 
post-transcriptional regulatory  elements20. Thus, some polymorphic sites at these segments have been associated 
with different HLA-G expression profiles.
While the HLA-G gene regulatory region variability may impact the magnitude of gene/protein expres-
sion, the coding region variability may impact the HLA-G biological properties. Differential transcriptional and 
post-transcriptional HLA-G activities have been associated with nucleotide variability at the promoter and 3’ 
untranslated  regions21–24. Additional sites potentially involved in HLA-G expression have also been reported for 
the HLA-G distal-promoter (located between − 2635 and − 1406 positions) and the proximal-promoter (located 
between − 1406 and − 1)25. Several regulatory elements can induce HLA-G expression, including progesterone 
responsive elements (PRE), heat shock element (HRE), interferon-sensitive response element (ISRE), while others 
may repress protein expression (RREB1—Ras-responsive element-binding protein 1; GLI3—Glioma Associated 
Oncogene Homologue 3)17. Besides the distal and proximal promoters, a 121-bp region 12 Kb upstream the 
HLA-G gene (Enhancer L) is reported to be a target for transcription factors (CEBP and GATA) associated with 
the placentation  process26.
A previous initiative addressing HLA-G diversity in worldwide samples was  reported27; however, this survey 
used a different sequencing technology and distinct genotyping and haplotyping methods; i.e., it was based 
on low-coverage data from the 1000 Genomes consortium phase I, which included a much lower number of 
 samples27. Other studies addressed specific samples from Brazil, Cyprus, and Benin, and characterized the 
full gene sequence and the proximal promoter but disregarded the distal promoter  region28–30. Many studies 
addressed HLA-G polymorphisms using Sanger sequencing in association studies, usually evaluating only a 
segment of the gene or specific exons (e.g.31–35, and many others).
This study explored the HLA-G genetic diversity and the evolutionary aspects in worldwide population 
samples by using a state-of-the-art method to characterize polymorphisms and haplotypes from high-coverage 
next-generation sequencing (NGS) data. We also provide the most comprehensive survey of the HLA-G genetic 
diversity across worldwide populations and resources for future analyses evaluating HLA-G polymorphisms in 
terms of disease association and functional studies.
Samples and methods used to characterize HLA‑G genetic diversity
We evaluated 4738 individuals from 88 different population samples from four datasets, all of them sequenced 
in high-coverage (> 30×) and processed through the same computational pipeline. The first dataset was the new 
high-coverage sequencing data of the 1000 Genomes  consortium36, the second consisted of 831 samples from 
the International Genome Sample Resource (IGSR)  consortium37, the third encompassed 1323 elderly Brazil-
ians from the Saúde, Bem-estar e Envelhecimento (SABE)  cohort38, and the fourth comprised the high coverage 
sequencing of 80 individuals from Southeast Asia and Oceania, including the Agta hunter-gatherer people 
from the Northern Luzon island, Philippines. The population samples and their sample sizes are in Table S1. In 
all cases, we started from a genome-wide BAM file with reads aligned to the reference hg38 genome (version 
hg38DH) by using BWA MEM (https:// sourc eforge. net/ proje cts/ bio- bwa/).
The method used to extract the HLA-G data is described in detail in a file (the supplementary methods) with 
a description of all methods and variables we used. This method also follows the same strategy used to char-
acterize HLA class I genes in Brazilian  samples38. Using a single pipeline to extract the data from all samples is 
essential to avoid biases in the genotyping and haplotyping procedures. In brief, we used the hla-mapper version 
4.0 to optimize read alignment in the HLA complex, minimizing alignment errors and cross-alignments that are 
commonly observed among HLA  genes39. We have called genotypes using GATK HaplotypeCaller in the GVCF 
mode (https:// gatk. broad insti tute. org) with a further refinement step using vcfx (www. caste lli- lab. net/ apps/ vcfx). 
This method allows the detection of any previously unknown HLA-G variant. The haplotype inference used both 
read-aware phasing (GATK ReadBackedPhasing) and probabilistic models with the workflow phasex/shapeit4 
(www. caste lli- lab. net/ apps/ phasex). Please refer to the file (supplementary methods) for details regarding the 
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mapping, genotyping, and haplotyping procedures. Applying the bioinformatic pipeline, 4640 samples (97.9%) 
passed the quality control and the haplotyping procedure, as presented in Table S1.
To support the quality of the data presented here, we evaluated departures of the Hardy–Weinberg expecta-
tions (HWE) at the SNP level in population samples with at least 10 individuals (63 populations out of 88). Of 
those, 55 (87.3%) present no HWE deviation, and 8 populations present just two deviations. Thus, most SNPs 
fit HWE.
Resources used to evaluate the HLA diversity. The method described above allowed us to retrieve 
SNP and haplotype data from approximately 7870 nucleotides surrounding the HLA-G gene, from 4328 bases 
upstream of the first translated ATG to 100 nucleotides downstream HLA-G. This large region includes most 
of the regulatory elements, all exons and all introns. We extracted coding (exons + introns), exonic (the CDS), 
promoter, and 3’UTR sequences. We also translated CDS sequences into proteins (the allotypes).
In the following sections, we will discuss the HLA-G polymorphisms across the world, providing insights 
regarding the HLA-G genetic diversity, and present a resource for future studies evaluating HLA-G polymor-
phisms and disease association studies in different populations. We also provide several useful tools to evaluate 
HLA-G diversity (Table 1) that can be downloaded from the website www. caste lli- lab. net/ HLA-G or are included 
as supplementary material.
Nomenclature, SNPs, nucleotide diversity, and linkage disequilibrium across HLA‑G
Due to the lack of a standardized nomenclature for the regulatory regions, individual regulatory region hap-
lotypes have been previously designated as “distal/proximal promoter regions”, and “3’UTR haplotypes”, as 
proposed by our  group29,40,41. Because the HLA-G region evaluated in this study includes an extensae region 
(from − 4328 upstream the first translated ATG to 100 nucleotides downstream the transcription end site), and 
there is no designated nomenclature to nominate the sequences we have characterized (for instance, when the 
sequence includes the complete promoter, all introns, and the complete 3’UTR sequence), we used the term 
GEMBIO_HLA-G_H1 (complete haplotype number 1, for HLA-G, available in the GeMBio laboratory Database) 
to designate this large gene sequence, which is available for download (Table 1). These names can be converted 
to whatever future nomenclature will be available and standardized. Whenever this complete nomenclature is 
used in this text, the previous names of the regulatory (Distal-G, PROMO-G, and 3’UTR) and coding region (as 
defined by the IPD-IMGT/HLA database) haplotypes are also mentioned.
We detected 442 different variants encompassing approximately 7870 nucleotides surrounding the HLA-G 
locus. The majority are bi-allelic single nucleotide exchanges, but there are some indels, multi-allelic variants 
and combinations of them. The list of each variant, with its reference and alternative alleles, and their global 
Table 1.  Resources available for download or listed as supplementary material regarding the HLA-G gene and 
its polymorphisms. a Available for download in www. caste lli- lab. net/ HLA-G.
Resource Description Availability
VCF listing all variants
A VCF file containing all variants, the reference and alternative alleles, and global counts, to 
be used as support for variant refinement when genotyping HLA-G in NGS procedures or 
variant annotation
For  downloada
Phased VCF A VCF file with the phased genotypes for each sample Upon request
FASTA file with full sequences A copy of every full-length sequence observed in this survey (approximately 12 Kb each), and their global counts For  download
a
FASTA file with gene sequences
The full sequence of each HLA-G allele (exons + introns) observed in this survey, with 
their global counts. Each sequence is identified with its official name according to the IPD-
IMGT/HLA database, or as a novel sequence
For  downloada
FASTA file with CDS sequences
We extracted all different exonic sequences (CDS). This file contains a copy of each different 
sequence, with their global counts. Each sequence is identified with its official name accord-
ing to the IPD-IMGT/HLA database, or as a novel sequence
For  downloada
FASTA file with protein sequences
We translated all exonic sequences into proteins (allotypes). This file contains a copy of 
each different sequence, with their global counts. Each sequence is identified with its official 
name according to the IPD-IMGT/HLA database, or as a novel sequence
For  downloada
FASTA file with 3’UTR sequences The sequence of each 3’UTR haplotype we have detected, with their names and global counts For  download
a
SNP frequencies This table provides the frequency for the reference and alternative alleles in the global popu-lation, in XLSX format Supplementary material (Table S2)
Genomic alleles (4-digit resolution) frequencies
This table provides the frequency for each genomic allele (4-digit resolution) in each popu-
lation we have studied, in XLSX format. There are 3 sheets, one for biogeographic regions, 
one for countries, and one for specific population samples
Supplementary material (Table S3)
Allotypes frequencies (2-digit resolution)
This table provides the frequency for each allotype (2-digit resolution, full-length protein) 
in each population we have studied, in XLSX format. There are 3 sheets, one for biogeo-
graphic regions, one for countries, and one for specific population samples
Supplementary material (Table S4)
3’UTR frequencies
This table provides the frequency for 3’UTR haplotype in each population we have studied, 
in XLSX format. There are 4 sheets, one for biogeographic regions, one for countries, one 
for specific population samples, and one describing the combination between genomic 
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frequencies, is available in Table S2. The VCF containing the phased genotypes of every individual is available 
upon request.
These 442 variants are arranged into 514 different haplotypes or full-length sequences (Table 1) and some of 
these haplotypes are quite common. The two most frequent ones are: (1) GEMBIO_HLA-G_H1 presents a fre-
quency of 21.6% and is associated with known haplotypes, such as the distal promoter Distal-010101a, the proxi-
mal promoter PROMO-G010101a, the coding allele G*01:01:01:01, and the 3’UTR haplotype known as UTR-01, 
and (2) GEMBIO_HLA-G_H2 presents a frequency of 10.8% and carries the distal promoter Distal-010102a, 
the proximal promoter PROMO-G010102a, the coding allele G*01:01:02:01, and UTR-0229,30. We observed 20 
full-length haplotypes presenting global frequencies higher than 1%, exhibiting a summed frequency of 76.85% 
(from GEMBIO_HLA-G_1 to GEMBIO_HLA-G_20). Thus, despite the presence of many variants, there are 
few full-length frequent haplotypes, reflecting the high Linkage Disequilibrium (LD) along the HLA-G locus. 
In Fig. 1, we present the LD pattern along the HLA-G locus for bi-allelic variants with a minor allele frequency 
(MAF) > 0.1% and fitting HWE (106 variants).
The entire HLA-G gene is included within a single segregation block. Although Fig. 1 illustrates the global LD 
pattern, we observed similar patterns when considering only samples from Europe, Africa, Asia, and American. 
Most of the pairwise comparisons present D’ = 1 (Fig. 1 and S1), and many comparisons present r2 > 0.8. We dem-
onstrate that this high LD extends at least 4 kb upstream HLA-G to 100 nucleotides downstream. Moreover, there 
are many variants in complete LD (r2 = 1.00). Of the 106 variants plotted in Fig. 1, 43 (40.6%) present another 
variant in complete LD. For instance, rs17875397 (position − 56) is in absolute LD with nine other variants, 
including rs17875400 (+ 507) and rs17875405 (+ 1534). There are also many variants in almost complete LD 
(measured by r2 > 0.95). For instance, considering the threshold r2 > 0.95, 55 selected SNPs can tag all 106 frequent 
variants along HLA-G. Because of that, LD among HLA-G variants must be considered when performing any 
association study to disregard hitchhiking effects. This high LD explains the presence of a few haplotypes that 
are frequent globally when analyzing almost 8 Kb surrounding HLA-G. This high LD was previously proposed 
evaluating other population  samples29,40, and it may extend at least more 20 Kb downstream the gene, where an 
Alu insertion accompanies the G*01:01:01:01  allele42, or even extend up the HLA-A locus43.
Figure 2 illustrates the frequency of each HLA-G variant (panel A), nucleotide diversity (panel B), SNP density 
(Panel C), and Tajima’s D (panel D) across the HLA-G region, in windows of 500 nucleotides and step size of 1, 
starting from 4 kb upstream HLA-G (the promoter region) to 200 nucleotides downstream it, considering all 
1000Genomes samples pooled together. To evaluate the significance of the parameters estimated from HLA-G, 
we built a null distribution considering the patterns observed in chromosome 6. For that purpose, we computed 
these statistics in 10,000 random windows of 500 nucleotides from chromosome 6. The values above the blue 
and red horizontal lines are higher than 99.9% and 99% of the ones observed in the null distribution for chro-
mosome 6, respectively. The orange line represents the average observed for each statistic. Similar patterns can 
Figure 1.  Linkage disequilibrium between pairs of 106 bi-allelic SNPs at the HLA-G gene region, starting from 
4 Kb upstream the gene up to 100 nucleotides downstream, all presenting a global minimum allele frequency 
of 1%. The image was generated in the Haploview and further edited by using Inkscape. Areas in black indicate 
strong LD (r2 > 0.8), shades of gray indicate moderate LD, and white indicates low LD.
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be observed in all biogeographic regions. This analysis has revealed interesting insights. Nucleotide diversity 
across HLA-G is usually higher than 0.4% (the red line), which is much higher than the average observed from 
chromosome 6 (0.082%). The regions with the highest nucleotide diversity (around 1%), which are among 
the 0.1% highest observed in chromosome 6 (blue line), coincides with the promoter region around positions 
− 3614 (green dot, rs1611163) and − 725 (yellow dot, rs1233334). Another very polymorphic region coincides 
with intron 2. Likewise, the strongest positive Tajima’s D signals in the promoter region, which is compatible 
with balancing selection, coincide with these two markers. The region surrounding marker − 3614 (rs1611163) 
presents many frequent variants, including rs1611164, rs1611165, rs1611166, rs1611167, rs2743926, rs1611168, 
rs11169, in a short segment of 336 bp. Likewise, the region surrounding maker − 725 presents many frequent 
variants, including rs2249863 (− 716), rs2735022 (− 689), rs35674592 (− 666), rs17875391 (− 646), and rs1632944 
(− 633), all previously described  elsewhere40. The position − 725 is a tri-allelic variant, which has been described 
as influencing HLA-G expression levels possibly by epigenetic  mechanisms44. Moreover, except for rs17875391, 
all these polymorphisms are listed as eQTLs for HLA-G expression by the GTEX portal (https:// gtexp ortal. 
org). It is not clear whether these variants directly influence HLA-G expression or if they are in LD with other 
regulatory elements, such as enhancer L, located 12 Kb upstream HLA-G26. However, the strongest signal of 
balancing selection coincides with intron 5 (Fig. 2, panel D), with the Tajima’s D values higher than 99.9% of the 
ones observed for chromosome 6.
When we consider the transcribed HLA-G segment, illustrated in the bottom panel at Fig. 2, and the posi-
tions and frequencies of variants across HLA-G (panel A), we noticed that most frequent variants coincide with 
intronic regions and that exon 4 is quite conserved. Table 2 presents the number of segregation sites, nucleotide 
diversity, and Tajima’s D in each HLA-G exon and intron. Introns 1 and 2 present two of the highest nucleotide 
diversity indexes across HLA-G (Table 2, Fig. 2) and the highest number of segregation sites in the sliding win-
dow analysis (Fig. 2). Some of the intronic SNPs are also considered eQTLs for HLA-G expression, according 
to GTEX data (https:// gtexp ortal. org). It is not clear whether these intronic variants directly influence HLA-G 
expression. However, as addressed throughout the following sections, these intronic variants (as haplotypes) are 
in almost complete LD with some promoter and 3’UTR haplotypes.
On the other hand, the nucleotide diversity drops to low levels in exons, except for exon 1, which is very short 
(Table 2) and presents two frequent synonymous variable sites. Additionally, the highest Tajima’ D coincides 
with introns, mostly intron 1, intron 2, and intron 5, all presenting positive Tajima’s D, which is compatible with 
balancing selection. In contrast, all exons present negative values, which is compatible with purifying selection 
(Table 2). Exon segments are conserved, and most of the exonic variants are synonymous mutations. Exon 2 
presents only two frequent variants, one non-synonymous associated with the allotype G*01:03, and the other 
a synonymous mutation. Exon 3 presents four common variants, two synonymous mutations, one non-synon-
ymous associated with allotype G*01:04, and one frameshift associated with allotype G*01:05. Exon 4 presents 
Figure 2.  Frequency of each variant (panel A), nucleotide diversity (panel B), number of segregation sites 
(panel C), and Tajima’s D (panel D) across HLA-G, considering all samples from the 1000Genomes project 
pooled together, starting from approximately 4 kb upstream the gene (the promoter region) to 100 nucleotides 
downstream HLA-G. Panels B, C, and D were computed in sliding windows of 500 nucleotides and a step size 
of 1. The HLA-G exon/intron structure is indicated in the bottom panel, with fine lines indicating introns and 
thick lines indicating exons. To evaluate the significance of the parameters estimated from HLA-G, we built 
a null distribution considering the patterns observed in chromosome 6, computing these statistics in 10,000 
random windows of 500 nucleotides from chromosome 6. The values above the blue and red horizontal lines are 
higher than 99.9% and 99% of the ones observed for chromosome 6, respectively. The orange line represents the 
average observed in chromosome 6 for each statistic. The green and the yellow dots represent polymorphisms 
-3614 (rs1611163) and − 725 (rs1233334), respectively.
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only three frequent variants, and one configures a non-synonymous mutation associated with allotype G*01:06. 
Other rare variants in exons are usually synonymous mutations.
We also calculated the ratio of substitution rates at non-synonymous and synonymous sites in exons (Table 3). 
Interestingly, none of the exons, when isolated, presented evidence of purifying selection. However, when pooled 
together, there is evidence of purifying selection at exons 2, 3, and 4 (Table 3). This phenomenon was observed 
in a previous study that evaluated a reduced number of  sequences45. Taken together, the nucleotide diversity 
and Tajima’s D patterns (Fig. 2 and Table 2), and the ratio of substitutions (Table 3), made it clear that HLA-G is 
indeed conserved in exons, although not necessarily conserved in introns and regulatory sequences. Nevertheless, 
nucleotide diversity for introns and the regulatory sequences are much higher than the human average (0.075%)46.
Most of the HLA-G common SNPs are shared worldwide. Because of that, there is a low population differen-
tiation (Fig. 3), except for very isolated populations that may have experienced strong bottleneck effects, such 
as the Aeta, Batak, and Pima.
The HLA‑G coding region diversity. We considered the diversity observed between position −300 
and + 838, which is the region tracked by the IPD-IMGT/HLA  database19, and included, in this survey, 191 vari-
ation sites. All coding sequences we have observed, together with their names and global counts, are available 
for download (Table 1). We detected 190 different HLA-G alleles; 36 of them were already reported (fully or 
partially) in the IPD-IMGT/HLA  database19, with a summed frequency of 95.54%. The 154 remaining sequences 
configure possible new HLA-G alleles. Because these new sequences have not been cloned and submitted to the 
IPD-IMGT/HLA, we named all new sequences as GEMBIO_HLA-G_G followed by a number that identifies 
this sequence in the GeMBio laboratory. Interestingly, at least 41 of these new alleles occurred more than once, 
and some are very frequent, such as GEMBIO_HLA-G_G144, with 51 copies detected in Africa, America, and 
the Middle East. We also confirmed the existence of many rare HLA-G alleles that have been submitted to the 
IPD-IMGT/HLA database, such as G*01:01:01:14Q (4 copies), G*01:09 (1 copy), G*01:11 (11 copies), G*01:14 
(6 copies), G*01:21 N (2 copies), G*01:26 (2 copies), and others (Table S3).
Table 2.  The number of segregation sites, nucleotide diversity, and Tajima’s D across different HLA-G regions in 
4640 samples from 88 different populations. *The indexes are scaled in shades of green, from white (the lowest 
value) to dark green (the highest value).
HLA-G region Segrega on sites Nucleo de diversity * Tajima's D * 
Promoter (upstream 4 kb) 219 0.0053 –0.0311 
Promoter (upstream 1.5 kb) 80 0.0052 –0.2009 
111noxE 0.0139 –0.2089 
111nortnI 0.0150 0.9949 
812noxE 0.0024 –1.3580 
912nortnI 0.0122 0.8360 
713noxE 0.0031 –0.9985 
233nortnI 0.0064 0.3521 
414noxE 0.0012 –1.4531 
64nortnI 0.0041 –0.2726 
015noxE 0.0073 –0.3035 
715nortnI 0.0072 1.6239 
16noxE 0.0000 –0.6670 
416nortnI 0.0038 –0.1377 
62RTU'3 0.0064 –0.2561 
Table 3.  Synonymous and nonsynonymous nucleotide substitution test of neutrality, positive, and purifying 
selection for analysis over 77 HLA-G sequences defined by exon mutations, in 4640 samples from 88 different 
populations. *Significant P-values are marked in boldface.
dN/dS neutrality test
Number of 
sequences Number of codons
HA = neutrality 
(dN ≠ dS)*
HA = positive 
selection (dN > dS)
HA = purifying 
selection (dN < dS)*
Exon 1 11 24 − 0.8576, P = 0.3928 − 0.9059, P = 1.0000 0.8804, P = 0.1902
Exon 2 19 90 − 1.1546, P = 0.2505 − 1.1160, P = 1.0000 1.1258, P = 0.1312
Exon 3 20 92 − 0.6806, P = 0.4973 − 0.6930, P = 1.0000 0.6790, P = 0.2491
Exon 4 17 92 − 1.0288, P = 0.3056 − 1.007, P = 1.0000 0.9609, P = 0.1692
Exon 5 10 39 − 1.5091, P = 0.1338 − 1.3480, P = 1.0000 1.4232, P = 0.0786
All exons 77 339 − 2.5808, P = 0.0110 − 2.5069, P = 1.0000 2.6134, P = 0.0050
Exons 2 and 3 39 182 − 1.3036, P = 0.1948 − 1.2308, P = 1.0000 1.2635, P = 0.1044
Exons 2, 3, and 4 55 274 − 1.7453, P = 0.0834 − 1.7482, P = 1.0000 1.6929, P = 0.0465
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In terms of global diversity, there are 14 HLA-G alleles with global frequencies higher than 1%: G*01:01:01:01, 
G*01:01:01:04, G*01:01:01:05, G*01:01:01:06, G*01:01:01:08, G*01:01:02:01, G*01:01:03:03, and G*01:01:22:01 
(all of them encoding the G*01:01 allotype), G*01:03:01:02 (encoding the G*01:03 allotype), G*01:04:01:01, 
G*01:04:01:02, and G*01:04:04 (encoding the G*01:04 allotype), G*01:05 N (the null allele), and G*01:06:01:01 
(encoding the G*01:06 allotype). These alleles represent 91% of all HLA-G sequences detected worldwide, 
and their frequencies differ in each biogeographic region (Fig. 4), and in each population sample (Table S3). 
For instance, the frequency of G*01:01:01:01 is high in East Asia, low in Africa, and rare in Oceania, while 
G*01:01:01:04 is quite rare in Asia and frequent in Africa (Fig. 4). The differentiation among populations, evalu-
ated by FST, became clearer when evaluated using the haplotypes/genomic alleles (Fig. 5) compared to SNPs 
(Fig. 3), with African, European, South Asian, and Southeast Asian population samples clustering together. 
However, most of the population samples amalgamate in the center of the plot, because the common HLA-G 
alleles are present worldwide (Fig. 5).
There are 74 alleles that have occurred at least twice. For instance, the new genomic allele named GEM-
BIO_HLA-G_G128 presents a frequency of 30% among the Aeta and around 10% in Agta and the Bouganville 
Island samples (Table S3). The hunter-gatherers in the Philippines (Agta) have been linked to Bouganville and 
Figure 3.  Multidimensional scaling (MDS) illustrating the distance (measured by FST estimated from HLA-
G SNPs) among population samples with at least 10 individuals. The name of each population is available at 
Table S1. We have indicated the names of some outliers.
Figure 4.  Frequencies of the most common HLA-G alleles, allotypes, and 3’UTR haplotypes in different 
population samples across the world. Tables S3, S4, and S5 present all frequency values.
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Highland Papua New Guinea and Australian hunter-gatherers, possibly associated with a previous out of  Africa47. 
The sequence GEMBIO_HLA-G_G31 occurred in many countries, achieving a frequency of 16.7% in the Central 
African Republic (Table S3). Both these new alleles encode the allotype G*01:01, which is the most frequent 
worldwide (Fig. 4). As explained earlier, these names represent sequences stored in the GeMBio laboratory 
Database (www. caste lli- lab. net/ HLA-G). Thus, HLA-G genetic diversity is higher than we currently acknowledge, 
although only a few different allotypes can be found worldwide. This observation reinforces the conservation in 
terms of protein diversity, but not necessarily in terms of DNA diversity. In fact, as demonstrated in the previous 
section, HLA-G nucleotide diversity is much higher than the one observed across chromosome 6, particularly 
in intronic regions. In addition, there is evidence of purifying selection acting on HLA-G exons, reinforcing the 
evidence of protein conservation in worldwide populations.
We have characterized the pair of full sequences of every individual using the cutting-edge sequencing tech-
nology, and we have described here, for the first time, the complete sequences (DNA and protein) of some alleles 
that are only partially reported in the IPD-IMGT/HLA Database. Additionally, we have provided the sequences 
of many new HLA-G alleles. Sequence characterization was simplified because many individuals presented the 
same full-length sequence for alleles G*01:01:14, G*01:01:15, G*01:01:19, G*01:04:05, G*01:11, and G*01:14, 
which are only partially characterized in the IPD-IMGT/HLA Database. Likewise, some new sequences occurred 
in more than ten individuals. This worldwide data clearly reveals that the IPD-IMGT/HLA is outdated in terms 
of stored data for HLA-G. It should be emphasized that, as new NGS initiatives grow, invaluable high-quality 
and large-scaled HLA data will be shortly produced. Thus, it is of utmost importance that the IPD-IMGT/HLA 
considers these data to update the official database.
The HLA‑G allotype/protein diversity. We have detected 53 different full-length proteins (allotypes), 
13 of them already reported by the IPD-IMGT/HLA database (Table S4). As already observed in many studies 
(www. allel efreq uenci es. net), only five allotypes are globally frequent (G*01:01, G*01:03, G*01:04, G*01:05 N, 
and G*01:06), with a summed frequency of 98.9%.
Some allotypes are particularly frequent in specific population samples (Table S4, Fig. 4). G*01:01 is the most 
frequent in all regions, except Oceania. G*01:06, for instance, is the product of a nucleotide exchange + 1799 C > T 
at codon 258 in exon 4, exchanging Threonine/Methionine (rs12722482, Table S1), and is frequent in the Middle 
East and South Asia, with intermediate frequencies in Europe and America, and almost absent in East Asia and 
Africa. Likewise, this allele was frequent in  Cyprus30, absent in other Amerindian tribes from  Brazil45 and  Benin28, 
and very rare in other Amerindians from South  America48. G*01:06 was previously associated with a risk for 
allograft  rejection49 and pregnancy  complications31,50,51, albeit the mechanisms underlying these associations are 
unknown. G*01:03, which results from an A > T exchange at position + 292 at exon 2, in codon 31, exchanging a 
Threonine for Serine (rs41551813, Table S1), is common among Africans, Americans (including Brazil), and in 
the Middle East, but rare among other biogeographic regions. Conversely, it is the most frequent allele among 
Karitiana (Table S4) and quite frequent in other Amerindian tribes from the Brazilian  Amazon45. The frequency 
of G*01:04, which is a consequence of the nucleotide exchange + 755 C > A at exon 3, exchanging Leucine/Isoleu-
cine (rs12722477, Table S1), is particularly high in Asia and Oceania, especially among Japanese. It is also high 
in Africa, Agta, and many Amerindians from South  America28,45,48 and less frequent in Europe. G*01:05 N, a 
truncated HLA-G protein caused by a deletion at exon 3 leading to a premature stop codon further in intron 4 
(rs41557518, Table S1), is rare in most regions but frequent in Africa. European populations present the highest 
Figure 5.  Multidimensional scaling (MDS) illustrating the distance (measured by FST estimated from HLA-G 
alleles—coding haplotypes) in populations samples with at least 10 individuals. The name of each population is 
available at Table S1. We have indicated the names of some outliers.
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frequency of allotype G*01:01, and usually the lowest frequency of other allotypes. Because of that, Europeans 
(especially Finns) present the lowest observed heterozygosity for allotypes across the world (data not shown).
Some HLA-G allotypes only occurred in specific populations. For example, G*01:11 occurred among Carib-
beans, African Americans, Puerto Ricans, and Brazilians, and G*01:14 among Caribbeans, Sierra Leoneans, and 
African Americans. Moreover, we detected at least 40 new allotypes. These new allotypes are usually rare and 
restricted to single populations. However, some have occurred more than once, such as the new allotype here 
named GEMBIO_HLA-G_P5 (P for protein sequence), which occurred in many samples from South East Asia 
and Oceania (Table S4), and it is a truncated protein sequence. The sequence of each allotype is available as a 
resource for download (Table 1).
In Fig. 6, we highlight all the important amino acid residues that may influence HLA-G function, and the 
polymorphic residues for allotypes that occurred at least twice in our dataset. Among these critical residues 
for HLA-G function, we may cite the Cysteine at the α1 domain (position 42 in the mature protein), which is 
responsible for dimer formation (C42-C42) among HLA-G membrane-bound and soluble isoforms, and dimers 
interact with more affinity with HLA-G  receptors4. The Methionine and Glutamine (76 and 79 at the mature 
protein, in green in Fig. 6) residues, also at the α1 domain, interact with  KIR2DL452. The residues 195 and 197, 
at the α3 domain, interact with ILT-2 and ILT-4 leukocyte receptors (purple and yellow in Fig. 7, respectively)53. 
The motif DQTQDVE, also at the α3 domain, interacts with the TCD8 receptor (in blue in Fig. 6)54. As can be 
observed, there is no variability at residues associated with HLA-G major biological properties in a worldwide 
sample. Note that truncated proteins lacking the α3 domain (G*01:05 N, G*01:21 N, and some new allotypes) 
present limited interaction with HLA-G receptors. However, the global frequency of these truncated allotypes 
is low (2.6%), mostly represented by G*01:05 N.
The HLA‑G 3’ untranslated region. The 3’ untranslated region (3’UTR) of most of the mRNA tran-
scripts is the primary target for microRNAs (miRNA), which are small non-coding RNA molecules that post-
transcriptionally modulate gene expression levels. MiRNAs modulate gene expression by two different mecha-
nisms, mRNA degradation and translation  blockage55. Variants in both miRNA coding gene and miRNA target 
sequence may influence miRNA/mRNA binding strength and thus influence gene expression  levels56.
The HLA-G 3’UTR segment was fully characterized in 2010 by Castelli and colleagues, analyzing a large 
admixed Brazilian sample using Sanger  sequencing41. There were eight frequent haplotypes in that survey, named 
UTR-01 to UTR-08, in order of frequency. Each of these 3’UTR haplotypes was in LD with specific HLA-G coding 
region alleles. The existence of these frequent haplotypes and their associated alleles were further confirmed by 
many other studies, using Sanger sequencing and NGS in different  populations24,27,28,30,40,57–67. There is a high LD 
between haplotypes from the HLA-G 3’UTR and the coding region (Fig. 1, Table 4), with each 3’UTR haplotype 
following specific HLA-G coding alleles, such as G*01:01:01:01-UTR-01, G*01:01:01:04-UTR-06, G*01:01:01:05-
UTR-04, G*01:03-UTR-05, G*01:04-UTR-03, and G*01:01:03-UTR-0741.
Figure 6.  HLA-G residues that are polymorphic or may influence HLA-G function, considering known 
allotypes detected in 4642 samples from across the world and new allotypes that have occurred at least twice. 
Polymorphic residues are marked in shades of gray. Important residues for the HLA-G function are marked in 
other colors. For allotypes with premature stop-codons, there is no amino acid indication after the frameshift 
mutation. In red, the Cysteine responsible for dimer formation. In green, the Methionine and Glutamine that 
interact with KIR2DL4. In purple and yellow, the important residues for ILT-2 and ILT-4 interaction. In blue, 
the motif DQTQDVE, which interacts with the TCD8 receptor.
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Although two consecutive exons form the HLA-G 3’UTR, the sequence after the stop codon at exon 6 does 
not present any variant. Thus, for the 3’UTR analysis, we have considered only the last HLA-G exon. According 
to transcripts NM_001363567 and NM_002127, the last HLA-G exon extends up to position 6:29,831,122 (hg38), 
which corresponds to the HLA-G position + 3292, when we consider the presence of the 14 bp  sequence15. Our 
data reinforce the presence of few nucleotide exchanges in the HLA-G 3’UTR, with 27 variants distributed across 
the last HLA-G exon. Of these, only nine are recognized as polymorphisms, with a global frequency superior to 
1%. Supplementary Table S2 displays the global frequency of each of these variants.
The 27 variants form 35 different haplotypes, with different frequencies across the globe, as shown in Fig. 4 
and Table S5. However, as initially described in 2010, only eight of these haplotypes are globally frequent (Fig. 4), 
with frequencies varying in different biogeographic regions. UTR-01 and UTR-02 are common in Europe, Africa, 
America, and parts of Asia, and less common in Southeast Asia and Oceania. UTR-01 and UTR-02 are the most 
divergent ones, but they are in LD with the HLA-G*01:01:01:01 and G*01:01:02:01 coding alleles (encoding the 
same G*01:01 allotype), which in turn are also the most divergent coding region alleles. Conversely, the frequen-
cies of UTR-03 and -07 follow the opposite path in terms of worldwide distribution, with the first associated with 
allotype G*01:04 and the last with G*01:01. UTR-07 is absent in Africa (Fig. 4).
The HLA-G 3’UTR presents at least three variants that have been evaluated in terms of functional studies. 
Undoubtedly, the most studied is the presence or absence of a 14-bp fragment at the beginning of the last HLA-
G exon, commonly referred to as the 14 bp INS/DEL (rs371194629) polymorphism. The ancestral allele is the 
presence of this sequence, which is detectable in most primates. The supplementary alignment provides its status 
in each 3’UTR sequence. The DEL allele is associated with the frequent UTR-01, UTR-03, UTR-04, UTR-06, and 
UTR-18 haplotypes (Fig. 4), among others. The ancestral allele (INS, presence) was associated with lower HLA-G 
production of the membrane-bound and soluble  isoforms68–71, while other studies pointed the  opposite72,73. 
Previous studies indicated that the 14-base sequence (or another variant in linkage with it) triggers alternative 
splicing removing from the mature HLA-G mRNA the first 92 bases of the last exon, which also includes the 14b 
 sequence74. These alternative mRNA seems to be more  stable75, but the fraction of mRNA that undergoes this 
alternative splicing varies in different cell lines and tissues. Moreover, the 14-bp polymorphism may influence 
the binding of a few miRNAs that target the 14b sequence directly, in addition to various miRNAs that target 
the 92b segment that may be spliced out when the 14b sequence is  present76,77. However, with the exception of 
miR-133a78, none of these interactions have been proven functionally.
The + 3142 G > C variant (rs1063320) influences the binding of some miRNAs, with Guanine allele favoring 
the targeting of three miRNAs, miR-148a-3p, miR-148b-3p, and miR-15256,76. However, while studies confirm 
that these miRNAs down-regulate HLA-G  expression79,80, apparently, they down-regulate HLA-G irrespectively 
of the nucleotide at position +  314280. Interestingly, miR-148a-3p and miR-148b also influence HLA-C expression, 
and both genes are co-expressed in the placenta during  pregnancy81. The allele associated with lower miRNA 
Figure 7.  Linkage disequilibrium encompassing the HLA-G and HLA-A region, considering 5347 
individuals from worldwide population samples and SNPs with minimum allele frequency higher than 
1%. We have removed variants that coincides with known structural variants, producing three continuous 
segments: chr6:29,823,675–29,874,064, starting from the HLA-G promoter up to 43 Kb downstream HLA-G, 
chr6:29,881,527–29,883,079, a 1.5 kb region between HLA-A and HLA-G, and chr6:29,938,412–29,945,862, 
starting 4 kb upstream HLA-A to the end of the HLA-A 3’UTR.
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binding, + 3142C, can be found worldwide and co-occurs with the frequent UTR-01, UTR-04, UTR-06, and 
UTR-18 haplotypes (Fig. 4, supplementary alignment).
The + 3187 A > G variant (rs9380142) coincides with an AU-rich motif in the HLA-G 3’UTR that may trigger 
HLA-G mRNA degradation. The presence of Guanine in this position reduces the size of this AU-rich motif, 
Table 4.  The relationship between HLA-G alleles and 3’UTR haplotypes, for combinations that have occurred 
at least twice in 4640 individuals across the globe. a The global frequency of this haplotype. b Considering all the 
3’UTR haplotypes associated with a given genomic allele, this is the frequency in which this specific 3’UTR 
haplotype follows the given genomic allele. An internal frequency of 1.000 indicates that the given genomic 
allele always presents the same 3’UTR sequence.
HLA-G allele 3’UTR haplotype Global  frequencya Internal  frequencyb
G*01:01:01:01 UTR-06 0.0027 0.0116
G*01:01:01:01 UTR-60 0.0002 0.0009
G*01:01:01:01 UTR-01 0.2277 0.9846
G*01:01:01:04 UTR-20 0.0036 0.1000
G*01:01:01:04 UTR-18 0.0198 0.5576
G*01:01:01:04 UTR-06 0.0121 0.3394
G*01:01:01:05 UTR-04 0.0704 0.9985
G*01:01:01:06 UTR-27 0.0002 0.0161
G*01:01:01:06 UTR-04 0.0131 0.9839
G*01:01:01:08 UTR-01 0.0204 1.0000
G*01:01:01:09 UTR-01 0.0033 1.0000
G*01:01:01:13 UTR-06 0.0066 1.0000
G*01:01:01:14Q UTR-01 0.0004 1.0000
G*01:01:02:01 UTR-02 0.1470 0.9956
G*01:01:02:01 UTR-10 0.0002 0.0015
G*01:01:02:02 UTR-02 0.0045 1.0000
G*01:01:02:04 UTR-02 0.0015 1.0000
G*01:01:03:03 UTR-07 0.0744 0.9957
G*01:01:03:03 UTR-31 0.0002 0.0029
G*01:01:03:04 UTR-07 0.0002 1.0000
G*01:01:12 UTR-02 0.0022 1.0000
G*01:01:14 UTR-02 0.0025 1.0000
G*01:01:15 UTR-06 0.0039 1.0000
G*01:01:17 UTR-02 0.0026 1.0000
G*01:01:19 UTR-02 0.0017 1.0000
G*01:01:22:01 UTR-02 0.0128 1.0000
G*01:01:22:04 UTR-02 0.0004 1.0000
G*01:03:01:02 UTR-56 0.0029 0.0510
G*01:03:01:02 UTR-17 0.0038 0.0662
G*01:03:01:02 UTR-48 0.0004 0.0076
G*01:03:01:02 UTR-05 0.0499 0.8752
G*01:04:01:01 UTR-03 0.1211 0.9799
G*01:04:01:01 UTR-02 0.0004 0.0035
G*01:04:01:01 UTR-13 0.0018 0.0148
G*01:04:01:02 UTR-53 0.0002 0.0227
G*01:04:01:02 UTR-03 0.0093 0.9773
G*01:04:04 UTR-23 0.0009 0.0171
G*01:04:04 UTR-03 0.0495 0.9829
G*01:04:05 UTR-03 0.0027 1.0000
G*01:05 N UTR-02 0.0243 1.0000
G*01:06:01:01 UTR-02 0.0484 1.0000
G*01:06:01:02 UTR-02 0.0009 1.0000
G*01:08:02 UTR-02 0.0003 1.0000
G*01:11 UTR-03 0.0009 1.0000
G*01:14 UTR-05 0.0006 1.0000
G*01:21 N UTR-03 0.0002 1.0000
G*01:26 UTR-02 0.0002 1.0000
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positively influencing mRNA stability and associated with higher HLA-G  expression82. The only frequent 3’UTR 
carrying the high-expressing allele (Guanine) is UTR-01.
Many studies addressed the influence of the 3’UTR sequence on the HLA-G expression levels of both mem-
brane-bound and soluble isoforms. Since HLA-G presents a high LD (Fig. 1), any study addressing HLA-G 
expression profile and polymorphism must consider how these polymorphisms interact with each other as hap-
lotypes. For instance, while UTR-04 and UTR-06 present the high-expressing + 3142 > C allele, they also carry 
the low-expressing + 3187 > A allele. The 14 bp INS allele usually co-occurs with the low expressing + 3142 > G 
and + 3187 > A alleles, with rare exceptions. The most divergent haplotypes, UTR-01 and UTR-02, differ in all the 
variants functionally reported to influence HLA-G expression and in two other positions (supplementary align-
ment). The coding alleles associated with these haplotypes encode the same HLA-G*01:01 allotype. It seems that 
the frequent 3’UTR haplotypes detected in modern humans somehow present polymorphisms that tune HLA-G 
expression in a dependent manner, possibly resulting in either high or low expression levels depending on the 
stimuli and the physiological microenvironment. The influence of specific haplotypes on the HLA-G expression 
levels has already been demonstrated  functionally24.
The relationship between the HLA-G 3’UTR haplotypes and HLA-G alleles was addressed in many 
 studies24,27,28,30,40–42,57–67, and was confirmed and updated in this survey (Table 4). Some HLA-G alleles, such as 
G*01:01:01:08, G*01:01:22:01, G*01:05 N, and G*01:06:01:01, always carry the same 3’UTR haplotype, while 
others, such as G*01:01:01:01, G*01:01:01:05, and G*01:01:01:06, are mostly, but not exclusively, associated 
with a single 3’UTR haplotype. Conversely, the G*01:01:01:04 and G*01:03:01:02 alleles present more than one 
frequent 3’UTR haplotype. Because of the impact of the 3’UTR sequence on the HLA-G function, this region 
should be included in the IPD-IMGT/HLA database, and the names of alleles carrying more than one 3’UTR 
haplotype should be updated. Table 4 lists only the haplotypes with a global frequency higher than 0.5%, which 
achieved a summed frequency of 95.3%. Following the internal frequencies presented in Table 4, one may argue 
that it is possible to input the HLA-G allotypes by observing a few SNPs at the 3’UTR segment. Table S5 presents 
a complete list of all genomic HLA-G alleles and their 3’UTR sequences.
Linkage disequilibrium between HLA‑G and HLA‑A. HLA-A is a classical class I gene that encodes a 
key molecule for antigen presentation. HLA-A is the second most variable histocompatibility gene, with more 
than 6000 alleles already described in the IPD-IMGT/HLA Database. As antigen presentation is the main func-
tion of HLA-A, it is common sense that natural selection has shaped the genetic variability in its coding region, 
increasing variability at the peptide binding site, thus allowing a great diversity of antigen  presentation83,84.
HLA-A and HLA-G are only 100 Kb apart from each other. This proximity results in high LD and hitchhiking 
effects might even involve common regulatory regions. Linkage disequilibrium between HLA-G and HLA-A has 
been previously demonstrated using low HLA-A typing  resolution43. Here, we demonstrate the LD level between 
these two genes by using forefront technology. First, we processed the region encompassing HLA-G and HLA-
A using the same pipeline, as described in the supplementary methods. Then, we removed variants laying on 
regions with known structural variants and rare variants (MAF < 1%), resulting in 1873 frequent SNPs covering 
the HLA-G, HLA-A, and their intergenic region. With this data, we calculated the r2 between pairs of bi-allelic 
SNPs (Fig. 7). Because we removed SNPs in regions with structural variants, we have 3 blocks of continuous vari-
ants: (a) chr6:29,823,675–29,874,064, starting from the HLA-G promoter up to 43 Kb downstream HLA-G, (b) 
chr6:29,881,527–29,883,079, a 1.5 kb region between HLA-A and HLA-G, and (c) chr6:29,938,412–29,945,862, 
starting 4 kb upstream HLA-A to the end of the HLA-A 3’UTR. Figure 7 demonstrates that the high LD across 
HLA-G extends from its promoter region up to HLA-A, with most pairwise r2 higher than 0.6.
This analysis also revealed some new insights involving the relationship between HLA-G alleles and HLA-A 
allotypes. For instance, there is an absolute LD (or almost absolute) between G*01:01:01:05 and A*03 (particu-
larly A*03:01), G*01:01:01:08 and A*30:02, G*01:01:01:13 and A*29:01, G*01:01:03:03 and A*11 (particularly 
A*11:01), G*01:01:02:01 and A*32:01, G*01:05 N and A*30:01, and G*01:06:01:01 and A*01:01. Conversely, the 
most frequent HLA-G alleles G*01:01:01:01, G*01:01:02:01, G*01:03:01:02, and G*01:04:01:01 are associated 
with multiple non-overlapping HLA-A allotypes. Therefore, it becomes clear that the LD between HLA-G and 
HLA-A is stronger than originally perceived.
Balancing selection has been well documented for both HLA-A83,85 and HLA-G86, but at different fashions. 
While the most polymorphic segment at HLA-A is the coding sequence, associated with the presence of frequent 
and divergent coding alleles in worldwide populations, the most polymorphic sites at HLA-G are the regulatory 
regions (i.e., promoter, introns, and the 3’UTR, Fig. 2). Many studies have detected signatures of balancing selec-
tion at the HLA-G promoter and 3’UTR 40,66,86,87, while the coding segment is conserved, as we demonstrated here, 
being under purifying selection. However, it is not clear whether balancing selection is indeed operating at the 
HLA-G promoter (for instance, in the region encompassing polymorphism − 725), or whether these findings are 
due to a hitchhiking effect caused by the selective pressures acting the neighboring HLA-A gene.
Since HLA-A is a crucial molecule for triggering adaptive immune responses, HLA-A is usually a target for 
natural selection. Balancing selection is an important force that maintains advantageous genetic diversity in 
populations, including variations responsible for long-term adaptation to the  environment88. For the coding 
region, it is well established that balancing selection deals with an excess of non-synonymous substitutions and 
an increase of functionally relevant variability.
A previous study from our group has proposed that the HLA-A locus is not influencing HLA-G, and therefore 
HLA-G is a direct target of  selection87. However, the study above addressed this issue using the 1000Genomes 
phase 1 data, which was the only dataset available at the time. Since then, several studies have revealed that the 
1000genomes phase I dataset at the HLA region is strongly affected by mapping bias. This mapping bias, together 
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with the fact that those samples were sequenced in a low coverage fashion, and no specific tools for HLA were 
applied, might have led to a wrong conclusion that HLA-A does not influence HLA-G.
Here, we demonstrate a strong LD between HLA-G and HLA-A in a way that the most frequent HLA-G alleles 
are associated with specific HLA-A alleles. Because there is a strong LD between any HLA-G allele and specific 
promoter and 3’UTR sequences, balancing selection operating at the HLA-A locus may also shapes the HLA-G 
promoter frequencies, downplaying its direct role on HLA-G. The same rationale can be applied to the HLA-G 
intronic sequences. High heterozygosity in HLA-A, which is commonly observed in worldwide populations, 
would lead to high heterozygosity in the HLA-G coding region (at the DNA level) and, thus, to high heterozygo-
sity in the HLA-G promoter and intronic  regions30,40. We cannot disregard the possibility that part of the genetic 
signature of balancing selection on HLA-A is due to HLA-G since the signatures of Natural Selection observed 
in both genes are not independent, as previous stated.
Implication of the HLA‑G variability in worldwide populations. After fully sequencing HLA-G 
and its promoter region in 4640 individuals from 88 different populations samples, we have concluded that 
this gene is highly conserved in the protein level, with no variation in the residues responsible for the bio-
logical function of the protein, i.e., dimer formation, alternative splicing, peptide coupling, and interaction with 
HLA-G receptors. Considering that HLA-G dimer interaction with HLA-G receptors is more stable than with 
 monomers17,53, and considering that dimer formation primarily depends on the disulfide bridge formed between 
Cysteine residues (C42–C42)53, as seen in Fig. 6, all complete proteins detected in worldwide samples exhibit 
Cysteine at residue 42. Then, theoretically, all proteins and the most common HLA-G isoforms exhibiting the 
α1 domain may form dimers. Since the mechanisms of HLA-G alternative splicing have not been completely 
defined, the frequent variants in the HLA-G introns may influence splicing, yielding different isoforms with 
different properties. In this context, some of these isoforms may not present the α1  domain17, avoiding dimer 
formation. Most of the HLA-G coding region variability coincides with introns (Fig. 2 and Table 2), and it is 
possible that these variants influence HLA-G regulation. All proteins we have detected exhibit no variability at 
residue motifs described to interact with ILT-2 (Phe195), ILT-4 (Phe195, Tyr197), KIR2DL4 (Met76, Gln79) and 
CD8 (DQTQDVE, residues 223–229)2,54,89. Nevertheless, isoforms presenting an incomplete α1 domain cannot 
interact with KIR2DL4, particularly the truncated HLA-G proteins encoded by the HLA-G*01:05 N, *01:13 N, 
and 01:21 N alleles (Fig. 6), as well as with ILTs and CD8 receptors.
Because HLA-G is a promiscuous immune checkpoint molecule, the modulation of its function may be tuned 
according to specific therapeutical approaches. The use of monoclonal antibodies against HLA-G in situations 
in which its expression is undesirable (for instance, in cancers and chronic viral disorders) would have many 
side effects since HLA-G is constitutively expressed in thymus, pancreas, and hematopoietic stem  cells17. On 
the other hand, the use of recombinant HLA-G would be a plausible alternative for allograft and autoimmune 
disease treatment. Since few coding allotypes (proteins) are most frequently observed in worldwide popula-
tions, the production of a small number of recombinant HLA-G proteins would be sufficient to individual-
ize treatment, according to the patient HLA-G coding region typing. Besides targeting the molecule, it is also 
possible to modulate its expression taking advantage of the knowledge of the target sites for transcription and 
post-transcription factors that act on the HLA-G gene expression. Considering the canonical and non-canonical 
miRNA and transcription  factor22,24,56,76,90–93 targeting HLA-G, a comprehensive survey of the HLA-G genetic 
diversity as provided in this study may help to unveil regulatory factors and strategies to differentially modulate 
HLA-G production whenever necessary.
Taken together, the results of this investigation indicate that: (1) most of the HLA-G polymorphic sites 
are located in the regulatory and intronic regions, (2) although some promoter segments present the highest 
nucleotide diversity and Tajima’s D, the strongest signals of balancing selection come from intronic segments, 
particularly intron 5 (3) a high LD is observed across HLA-G, from 4 Kb upstream the gene up to the HLA-A 
locus, (4) it is possible that balancing selection acting on HLA-A may be influencing the high heterozygosity 
observed in the regulatory and intronic sequences of HLA-G, and vice-versa, (5) the presence of few proteins 
frequently observed in worldwide populations corroborates the role of the HLA-G as an immune checkpoint 
molecule rather than as an antigen-presenting molecule; (6) the lack of variation in residues responsible for 
major HLA-G biological functions reinforces the immunomodulatory properties of the molecule, maintained 
throughout evolution; (7) most common variation sites within HLA-G regulatory and coding region have been 
maintained as haplotypes, as observed in worldwide populations, (8) motifs associated with HLA-G interaction 
with receptors may be engineered modified to impede or enhance receptor interaction according to the underly-
ing disorder, (9) possible therapeutic use of HLA-G as an immune checkpoint agent may be accomplished with 
the production of a limited number of recombinant proteins.
Concluding remarks
This is the most comprehensive study of the genetic diversity involving HLA-G performed so far. This large 
dataset, composed of populations from different ancestries and biogeographical regions and using sequencing 
data produced with cutting-edge sequencing technology and bioinformatics pipelines, may provide a broad 
picture of worldwide patterns of HLA-G haplotype distribution and linkage disequilibrium. This landmark 
achievement on HLA-G genetic diversity that will hardly be overridden in the near future provides all the basis 
for in-depth association and functional studies, which is of utmost importance given the immunomodulatory 
properties of the molecule.
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